Cases

Governments worldwide are rolling out digital identity systems to streamline access to healthcare, welfare, voting, and taxation. India's Aadhaar, Estonia's e-Residency, and the EU's Digital Identity Wallet represent different models balancing efficiency, inclusion, and privacy. Proponents argue digital IDs reduce fraud, improve service delivery, and enhance civic participation. Critics warn of surveillance overreach, exclusion of marginalized groups (e.g., unhoused or elderly populations), and cybersecurity vulnerabilities. In the U.S., pilot programs in states like Colorado and New York have sparked debate over federal standards. With AI-driven identity verification advancing rapidly and concerns about election integrity growing, this trial asks whether democracies should make digital IDs a prerequisite for accessing essential public services.

In 2026, AI-driven beauty startups like SkinMind and FormulAI are launching skincare products developed entirely by machine learning models trained on dermatological databases and ingredient interaction maps. These algorithms predict efficacy, stability, and irritation potential without traditional lab testing or human trials. While companies claim faster, personalized formulations with reduced animal testing, dermatologists and regulatory bodies warn that AI cannot fully replicate human skin variability or long-term safety outcomes. The FDA has not yet issued guidance on AI-formulated cosmetics, creating a regulatory gray zone. Consumers are drawn to hyper-personalized serums but may be unaware that these products lack the emulsion stability testing or transdermal absorption studies required for conventional brands. This trial examines whether algorithmic innovation justifies bypassing established product efficacy and safety protocols.

The term 'clean beauty' remains unregulated globally, allowing brands to market products as 'non-toxic' or 'natural' without third-party verification. In 2026, the FTC issued warning letters to 12 beauty companies for misleading 'clean' labeling, while the EU considers mandating organic certification for any product making environmental or health safety claims. Advocates argue that without standards like COSMOS or USDA Organic, consumers cannot distinguish between genuinely sustainable formulations and greenwashing. Opponents say rigid certification excludes effective synthetics (like lab-stable vitamin C derivatives) and disadvantages small brands that can't afford audits. This trial examines whether the 'clean beauty' movement needs standardized organic verification to maintain credibility and protect consumers.

Following a landmark 2025 lawsuit where a major fashion house was found liable for profiting from Indigenous textile patterns without consent or compensation, design schools are reevaluating curricula. The case, involving unauthorized use of Navajo weaving motifs in a luxury knitwear line, set a precedent for intellectual property claims based on cultural heritage. Institutions like Parsons and Central Saint Martins now face pressure to integrate mandatory modules on cultural representation, collaborative co-creation protocols, and ethical sourcing of traditional aesthetics. Critics argue this may stifle creative reinterpretation, while advocates say it corrects decades of extractive design practices. This trial addresses whether legal liability should drive pedagogical change in how future designers engage with global aesthetic traditions.

Wearable smart textiles embedded with nanosensors are now capable of monitoring skin hydration, UV exposure, pH levels, and inflammatory markers in real time. Companies like ChronoSkin and DermaWeave market these garments as early-warning systems for eczema flare-ups or melanoma risk. However, dermatologists caution that consumer-grade sensors lack the calibration and validation of medical devices. The FDA has not cleared most of these textiles as diagnostic tools, yet marketing often implies clinical utility. With rising telehealth adoption, patients increasingly rely on such data for self-management, raising concerns about false reassurance or unnecessary anxiety. This trial weighs the potential of wearable technology to democratize skin health monitoring against risks of unvalidated medical claims and data privacy issues.

In 2024–2025, several U.S. museums—including the Baltimore Museum of Art and the Everson Museum—have faced intense scrutiny and backlash after proposing to sell artworks from their collections (deaccessioning) to fund diversity, equity, and inclusion (DEI) programs, staff salaries, and operational costs. Traditionally, the Association of Art Museum Directors (AAMD) strictly limited deaccessioning proceeds to acquiring new art, but it temporarily relaxed these rules during the pandemic. Some institutions now argue that sustaining inclusive staffing and community engagement is as vital as growing collections. Critics, including major donors and art historians, warn that selling masterpieces for operating expenses erodes public trust, commodifies cultural heritage, and sets dangerous precedents. The debate centers on whether museums' missions should prioritize stewardship of physical collections or equitable access and representation. This dilemma forces the arts community to weigh institutional survival against long-standing ethical norms in art conservation and museum practice.

Following controversies like the removal of Sam Durant's 'Scaffold' (2017) and ongoing debates over monuments, cities including Chicago, Los Angeles, and Toronto have adopted policies requiring community input—or even co-design—in public art commissions. In 2025, a proposed sculpture in Brooklyn sparked protest when residents felt excluded from the selection process, despite the artist's national reputation. Advocates argue that public art funded by taxpayers must reflect local identity, history, and values, and that co-creation fosters ownership and reduces backlash. Critics caution that excessive consensus-building may dilute artistic vision, discourage bold conceptual work, or privilege vocal minorities over broader aesthetic considerations. This trial examines whether collaborative processes enhance or compromise the integrity and impact of public art.

In 2025, leading art institutions like the Royal College of Art and Parsons School of Design are integrating generative AI into foundational courses, sparking debate among educators, students, and practicing artists. Proponents argue that fluency in AI tools—such as Midjourney, Stable Diffusion, and Runway ML—is essential for contemporary creative careers in illustration, concept art, and design. Critics worry that prioritizing AI may erode foundational skills in drawing, color theory, and material handling, producing graduates who rely on algorithms rather than developing unique visual languages. The tension reflects a broader question: should art education preserve classical techniques as non-negotiable, or adapt fluidly to technological shifts? This trial examines the balance between tradition and innovation in shaping the next generation of artists.

Following the DEA's temporary pandemic-era rules allowing telehealth prescribing of Schedule II–V controlled substances (e.g., stimulants for ADHD, benzodiazepines for anxiety), a 2025 rule proposal seeks to extend these flexibilities permanently—but with conditions. The debate centers on access versus safety: rural and underserved patients benefit from virtual access to psychiatrists, yet concerns persist about diversion, misdiagnosis, and inadequate physical evaluation. Recent data shows a 300% increase in telehealth ADHD diagnoses since 2020, with some clinics operating on a 'diagnose-and-prescribe' model lacking comprehensive assessment. As the DEA finalizes rules in mid-2025, clinicians must weigh equity against stewardship. Should first-time prescriptions of controlled psychotropics require an in-person visit, or is virtual evaluation sufficient with proper safeguards?

GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) have revolutionized weight management, showing significant efficacy in clinical trials for individuals with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27). However, their off-label use is surging among individuals with normal or slightly elevated BMI seeking aesthetic or preventive benefits. In early 2025, the FDA reaffirmed that these drugs are not approved for cosmetic weight loss, citing risks including gastrointestinal side effects, muscle loss, and potential thyroid C-cell tumors (in rodent studies). Meanwhile, proponents argue that early metabolic intervention could prevent future disease, and that body composition—not just BMI—should guide eligibility. This dilemma confronts clinicians, patients, and insurers: should access be restricted to medically defined obesity, or expanded based on individualized metabolic risk and patient autonomy?